| ACAT抑制剂的研究进展 |
| |
| 引用本文： | 丁德荣,沈竞康. ACAT抑制剂的研究进展[J]. 中国新药杂志, 2005, 14(4): 396-400 |
| |
| 作者姓名： | 丁德荣 沈竞康 |
| |
| 作者单位： | 中国科学院上海药物研究所合成室,上海,201203 |
| |
| 摘 要： | 酰基辅酶A-胆固醇酰基转移酶(Acyl-CoA:Cholesterol Acyltransferase,ACAT)在生物体内催化胆固醇与长链脂肪酸连接形成胆固醇酯,在胆固醇的吸收、运输和贮存过程中起重要作用.抑制ACAT可降低血浆总胆固醇及低密度脂蛋白胆固醇水平,防止胆固醇酯化,减少胆固醇酯在动脉壁上积蓄,阻止动脉粥样硬化的形成.A-CAT抑制剂可能成为一类新型的降血脂与抗动脉粥样硬化药物.综述近几年来ACAT抑制剂的研究状况.
|
| 关 键 词： | ACAT抑制剂 动脉粥样硬化 胆固醇酯 降血脂 |
| 文章编号： | 1003-3734(2005)04-0396-05 |
Current status of studies on Acyl-CoA: Cholesterol Acyltransferase(ACAT)inhibitors |
| |
| DING De-rong,SHEN Jing-Kang. Current status of studies on Acyl-CoA: Cholesterol Acyltransferase(ACAT)inhibitors[J]. Chinese Journal of New Drugs, 2005, 14(4): 396-400 |
| |
| Authors: | DING De-rong SHEN Jing-Kang |
| |
| Abstract: | Acyl-CoA: Cholesterol Acyltransferase (ACAT) catalyzes cholesterol esterification, regulates intracellular free cholesterol levels, and promotes both cholesterol absorption in the small intestine and assembly of low-density lipoprotein (LDL) in the liver. ACAT inhibitors demonstrate cholesterol-lowering and antiatherosclerotic activities by blocking intestinal absorption of dietary cholesterol, inhibiting hepatic secretion of LDL, and preventing the formation of foam cells in the arterial wall. ACAT inhibitors have been regarded as potential lipid-lowering therapies and anti-atherosclerotic therapies. This review presents the current status of ACAT inhibitors in recent years. |
| |
| Keywords: | ACAT inhibitor atherosclerosis cholesterol-lowering lipid-lowering |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
